Quantcast

Latest Influenza treatment Stories

2010-03-18 10:16:18

Treating virulent influenza, sepsis, and other potentially deadly infections long has focused on looking for ways to kill viruses and bacteria. But new research from the University of Utah and Utah State University shows that modulating the body's own overeager inflammatory response to infection may help save more lives. In a study published March 17 in Science Translational Medicine, researchers led by U of U cardiologist Dean Y. Li, M.D., Ph.D., professor of internal medicine and director...

2010-02-08 10:00:00

SAN DIEGO, Calif., Feb. 8 /PRNewswire/ -- NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase(®)), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions. DAS181 is a broad...

2010-01-20 14:34:03

St. Jude Children's Research Hospital scientists lead effort that identifies a novel way statins protect cells from a host of bacterial toxins New research suggests a family of widely used cholesterol-lowering drugs might help protect individuals from serious illness following bacterial infection, including the pneumococcal infections that pose a deadly threat to those with sickle cell disease. Research led by St. Jude Children's Research Hospital investigators reported that drugs called...

2010-01-13 06:00:00

BIRMINGHAM, Ala., Jan. 13 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its partner, Shionogi & Co., Ltd. has received marketing and manufacturing approval for intravenous (i.v.) peramivir to treat patients with influenza in Japan. Shionogi intends to commercially launch peramivir under the commercial name RAPIACTA in Japan, pending the product's National Health Insurance (NHI) price listing. As a result of this approval, BioCryst will...

2009-12-02 09:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 2 /PRNewswirel/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has begun shipping additional quantities of Tamiflu® (oseltamivir phosphate) oral suspension (liquid). The added supplies of Tamiflu will begin arriving in pharmacies nationwide and will continue to roll out to wholesale and retail pharmacies during the next several weeks. These shipments add to the millions of treatment courses of the adult-sized capsules...

2009-11-19 07:30:00

EMERYVILLE, Calif., Nov. 19 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for...

2009-11-06 08:30:00

SAN DIEGO, Nov. 6 /PRNewswire/ -- NexBio Inc., in collaboration with scientists at the Centers for Disease Control and Prevention (CDC), St. Louis University, and the University of Hong Kong, announced today the publication of two articles in the peer-reviewed journal PLoS ONE. These two published studies suggest that DAS181 (Fludase®) may play a potentially important role for the treatment and prevention of the Pandemic Influenza A(H1N1) and drug-resistant influenza....

2009-10-27 14:29:01

An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases. In laboratory testing, the triple combination of oseltamivir (Tamiflu), amantadine (Symmetrel) and ribavirin showed a significant capacity to stop flu-virus growth, says Mark Prichard, Ph.D, who serves on...

2009-10-23 19:00:00

SILVER SPRING, Md., Oct. 23 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration announced today that, in response to a request from the U.S. Centers for Disease Control and Prevention, it has issued an emergency use authorization (EUA) for the investigational antiviral drug peramivir intravenous (IV) in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital. (Logo:...

2009-10-15 14:58:00

SILVER SPRING, Md., Oct. 15 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned consumers to use extreme care when purchasing any products over the Internet that claim to diagnose, prevent, treat or cure the H1N1 influenza virus. The warning comes after the FDA recently purchased and analyzed several products represented online as Tamiflu (oseltamivir), which may pose risks to patients. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) One of the...


Latest Influenza treatment Reference Libraries

69_d42a67c9e67a58fec0ffaab2b08808b2
2011-01-12 16:27:29

The common cold is a viral disease of the upper respiratory system, caused primarily by rhinoviruses and coronaviruses. Symptoms usually include a cough, sore throat, runny nose, and a fever. There is no known treatment to shorten the duration of the virus yet the cold normally dissipates after 7 to 10 days. It is the most common infectious disease in humans who on average are infected two to four times a year in adults. It can also be called a upper respiratory tract infection. Other...

More Articles (1 articles) »
Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related